This site is intended for health professionals only
Tuesday 18 December 2018
LatestNews
Share |

Latest News

European Commission approval for self-administration of Xolair® across all indications

Monday 17th December 2018
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
 
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
 
Xolair,...
Fri, 12 Oct 2018
The new unit will focus on digital diagnostics and help laboratories, hospitals and other healthcare providers to 'optimise' their performance
Fri, 5 Oct 2018
The introduction of dose banding and the recent publication of product specifications by NHS England have set the ball in motion for the introduction of licensed standardised chemotherapy doses, the benefits of which are discussed here